DPP-4 Inhibitor Reduces Central Blood Pressure in a Diabetic and Hypertensive Patient: A Case Report

Overview

Journal Medicine (Baltimore)

Specialty General Medicine

Date 2015 Jul 14

PMID 26166078

Citations 4

Authors

Luciana Neves Cosenso-Martin

Luiz Tadeu Giollo-Junior

Jose Fernando Vilela-Martin

Affiliations

Soon will be listed here.

Abstract

Hypertension and type 2 diabetes mellitus (DM) are among the main risk factors for the development of cardiovascular disease. Pharmacotherapy for DM should not only improve blood glucose control, but also provide beneficial glucose-independent cardiovascular effects. The central systolic blood pressure (SBP) has become more important than the brachial SBP in the assessment of cardiovascular risk.This case report describes the effect of vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, on the central SBP in a 54-year-old woman with hypertension and DM. She was submitted to applanation tonometry (AT) before and after vildagliptin association. AT of the radial artery is a non-invasive method that indirectly assesses arterial stiffness by calculating the central SBP and the augmentation index (AIx).After 3 months of follow-up using vildagliptin, central SBP and AIx were improved. Moreover, she presented better glycemic control.This case suggests an effect of DPP-4 inhibitor on arterial stiffness parameter (central SBP) in a hypertensive and diabetic patient, which shows a glucose-independent beneficial cardiovascular effect of this group of drugs.

Citing Articles

Blood Pressure-Lowering Effect of Newer Antihyperglycemic Agents (SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors).

Liakos C, Papadopoulos D, Sanidas E, Markou M, Hatziagelaki E, Grassos C Am J Cardiovasc Drugs. 2020; 21(2):123-137.

PMID: 32780214 DOI: 10.1007/s40256-020-00423-z.

Untargeted Metabolomics of Fermented Rice Using UHPLC Q-TOF MS/MS Reveals an Abundance of Potential Antihypertensive Compounds.

Daliri E, Ofosu F, Chelliah R, Kim J, Kim J, Yoo D Foods. 2020; 9(8).

PMID: 32726971 PMC: 7466378. DOI: 10.3390/foods9081007.

A Practical Approach to Hypertension Management in Diabetes.

Shaikh A Diabetes Ther. 2017; 8(5):981-989.

PMID: 28929319 PMC: 5630564. DOI: 10.1007/s13300-017-0310-3.

Twelve-week randomized study to compare the effect of vildagliptin vs. glibenclamide both added-on to metformin on endothelium function in patients with type 2 diabetes and hypertension.

Cosenso-Martin L, Giollo-Junior L, Martineli D, Cesarino C, Arruda Nakazone M, Cipullo J Diabetol Metab Syndr. 2015; 7:70.

PMID: 26312070 PMC: 4550051. DOI: 10.1186/s13098-015-0062-z.

References

DeLoach S, Townsend R . Vascular stiffness: its measurement and significance for epidemiologic and outcome studies. Clin J Am Soc Nephrol. 2008; 3(1):184-92. DOI: 10.2215/CJN.03340807. View

Ogawa S, Ishiki M, Nako K, Okamura M, Senda M, Mori T . Sitagliptin, a dipeptidyl peptidase-4 inhibitor, decreases systolic blood pressure in Japanese hypertensive patients with type 2 diabetes. Tohoku J Exp Med. 2011; 223(2):133-5. DOI: 10.1620/tjem.223.133. View

Lee Y, Park M, Choung J, Kim S, Oh H, Choi C . Glucagon-like peptide-1 inhibits adipose tissue macrophage infiltration and inflammation in an obese mouse model of diabetes. Diabetologia. 2012; 55(9):2456-68. DOI: 10.1007/s00125-012-2592-3. View

Barbieri M, Rizzo M, Marfella R, Boccardi V, Esposito A, Pansini A . Decreased carotid atherosclerotic process by control of daily acute glucose fluctuations in diabetic patients treated by DPP-IV inhibitors. Atherosclerosis. 2013; 227(2):349-54. DOI: 10.1016/j.atherosclerosis.2012.12.018. View

Samaras K, Viardot A, Lee P, Jenkins A, Botelho N, Bakopanos A . Reduced arterial stiffness after weight loss in obese type 2 diabetes and impaired glucose tolerance: the role of immune cell activation and insulin resistance. Diab Vasc Dis Res. 2012; 10(1):40-8. DOI: 10.1177/1479164112443375. View

Patvardhan E, Heffernan K, Ruan J, Hession M, Warner P, Karas R . Augmentation index derived from peripheral arterial tonometry correlates with cardiovascular risk factors. Cardiol Res Pract. 2011; 2011:253758. PMC: 3138105. DOI: 10.4061/2011/253758. View

Velija-Asimi Z, Izetbegovic S, Karamehic J, Coric J, Panjeta M, Macic-Dzankovic A . The effects of dipeptidyl peptidase-4 inhibitors in treatment of obese patients with type 2 diabetes. Med Arch. 2014; 67(5):365-7. DOI: 10.5455/medarh.2013.67.365-367. View

Westman E, Yancy Jr W, Mavropoulos J, Marquart M, McDuffie J . The effect of a low-carbohydrate, ketogenic diet versus a low-glycemic index diet on glycemic control in type 2 diabetes mellitus. Nutr Metab (Lond). 2008; 5:36. PMC: 2633336. DOI: 10.1186/1743-7075-5-36. View

Bakker W, Eringa E, Sipkema P, van Hinsbergh V . Endothelial dysfunction and diabetes: roles of hyperglycemia, impaired insulin signaling and obesity. Cell Tissue Res. 2008; 335(1):165-89. DOI: 10.1007/s00441-008-0685-6. View

10.

Mitchell G, Hwang S, Vasan R, Larson M, Pencina M, Hamburg N . Arterial stiffness and cardiovascular events: the Framingham Heart Study. Circulation. 2010; 121(4):505-11. PMC: 2836717. DOI: 10.1161/CIRCULATIONAHA.109.886655. View

11.

Haimoto H, Iwata M, Wakai K, Umegaki H . Long-term effects of a diet loosely restricting carbohydrates on HbA1c levels, BMI and tapering of sulfonylureas in type 2 diabetes: a 2-year follow-up study. Diabetes Res Clin Pract. 2007; 79(2):350-6. DOI: 10.1016/j.diabres.2007.09.009. View

12.

Bradley U, Spence M, Courtney C, McKinley M, Ennis C, McCance D . Low-fat versus low-carbohydrate weight reduction diets: effects on weight loss, insulin resistance, and cardiovascular risk: a randomized control trial. Diabetes. 2009; 58(12):2741-8. PMC: 2780863. DOI: 10.2337/db09-0098. View

13.

Tousoulis D, Antoniades C, Stefanadis C . Evaluating endothelial function in humans: a guide to invasive and non-invasive techniques. Heart. 2005; 91(4):553-8. PMC: 1768833. DOI: 10.1136/hrt.2003.032847. View

14.

van Poppel P, Netea M, Smits P, Tack C . Vildagliptin improves endothelium-dependent vasodilatation in type 2 diabetes. Diabetes Care. 2011; 34(9):2072-7. PMC: 3161271. DOI: 10.2337/dc10-2421. View

15.

Fadini G, Boscaro E, Albiero M, Menegazzo L, Frison V, De Kreutzenberg S . The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha. Diabetes Care. 2010; 33(7):1607-9. PMC: 2890368. DOI: 10.2337/dc10-0187. View

16.

Agabiti-Rosei E, Mancia G, ORourke M, Roman M, Safar M, Smulyan H . Central blood pressure measurements and antihypertensive therapy: a consensus document. Hypertension. 2007; 50(1):154-60. DOI: 10.1161/HYPERTENSIONAHA.107.090068. View

17.

Mason R, Jacob R, Kubant R, Ciszewski A, Corbalan J, Malinski T . Dipeptidyl peptidase-4 inhibition with saxagliptin enhanced nitric oxide release and reduced blood pressure and sICAM-1 levels in hypertensive rats. J Cardiovasc Pharmacol. 2012; 60(5):467-73. DOI: 10.1097/FJC.0b013e31826be204. View

18.

Matsubara J, Sugiyama S, Akiyama E, Iwashita S, Kurokawa H, Ohba K . Dipeptidyl peptidase-4 inhibitor, sitagliptin, improves endothelial dysfunction in association with its anti-inflammatory effects in patients with coronary artery disease and uncontrolled diabetes. Circ J. 2013; 77(5):1337-44. DOI: 10.1253/circj.cj-12-1168. View

19.

Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M . 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013; 31(7):1281-357. DOI: 10.1097/01.hjh.0000431740.32696.cc. View

20.

Drucker D, Nauck M . The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006; 368(9548):1696-705. DOI: 10.1016/S0140-6736(06)69705-5. View